SG11202109781QA - Uses of phosphodiesterase inhibitors - Google Patents
Uses of phosphodiesterase inhibitorsInfo
- Publication number
- SG11202109781QA SG11202109781QA SG11202109781QA SG11202109781QA SG 11202109781Q A SG11202109781Q A SG 11202109781QA SG 11202109781Q A SG11202109781Q A SG 11202109781QA SG 11202109781Q A SG11202109781Q A SG 11202109781QA
- Authority
- SG
- Singapore
- Prior art keywords
- phosphodiesterase inhibitors
- phosphodiesterase
- inhibitors
- Prior art date
Links
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 title 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Lubricants (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910174522 | 2019-03-08 | ||
| CN201910235722 | 2019-03-27 | ||
| PCT/CN2020/078215 WO2020182076A1 (zh) | 2019-03-08 | 2020-03-06 | 磷酸二酯酶抑制剂的用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202109781QA true SG11202109781QA (en) | 2021-10-28 |
Family
ID=72382604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202109781Q SG11202109781QA (en) | 2019-03-08 | 2020-03-06 | Uses of phosphodiesterase inhibitors |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220160696A1 (zh) |
| EP (1) | EP3939588A4 (zh) |
| JP (1) | JP7404616B2 (zh) |
| KR (1) | KR20210136104A (zh) |
| CN (1) | CN111658653B (zh) |
| AU (1) | AU2020235187B8 (zh) |
| CA (1) | CA3132895C (zh) |
| SG (1) | SG11202109781QA (zh) |
| TW (1) | TWI816026B (zh) |
| WO (1) | WO2020182076A1 (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111471059B (zh) * | 2019-01-23 | 2022-12-02 | 药捷安康(南京)科技股份有限公司 | Pde9抑制剂及其用途 |
| AU2020393384A1 (en) | 2019-11-28 | 2022-06-09 | Bayer Aktiengesellschaft | Substituted aminoquinolones as DGKalpha inhibitors for immune activation |
| US20230062100A1 (en) | 2019-11-28 | 2023-03-02 | Bayer Aktiengesellschaft | Substituted aminoquinolones as dgkalpha inhibitors for immune activation |
| TW202304431A (zh) | 2021-04-01 | 2023-02-01 | 大陸商藥捷安康(南京)科技股份有限公司 | 磷酸二酯酶抑制劑的製備方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3373838B2 (ja) * | 1999-10-25 | 2003-02-04 | 山之内製薬株式会社 | ナフチリジン誘導体 |
| AR029185A1 (es) * | 1999-10-25 | 2003-06-18 | Yamanouchi Pharma Co Ltd | Derivado de naftiridina |
| JP2004505980A (ja) * | 2000-08-09 | 2004-02-26 | アルミラル プロデスファルマ ソシエダ アノニマ | ピロロトリアゾロピリミジノン誘導体 |
| HN2002000317A (es) * | 2001-11-02 | 2003-05-21 | Pfizer | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares |
| DE10156249A1 (de) * | 2001-11-15 | 2003-05-28 | Bayer Ag | Regulation der cGMP-spezifischen Phosphodiesterase 9A |
| CA2531506A1 (en) * | 2003-08-22 | 2005-03-10 | Avanir Pharmaceuticals | Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases |
| US7825131B2 (en) * | 2003-09-23 | 2010-11-02 | Merck Sharp & Dohme Corp. | Quinoline potassium channel inhibitors |
| EP1579862A1 (en) * | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
| TWI404721B (zh) * | 2009-01-26 | 2013-08-11 | Pfizer | 胺基－雜環化合物 |
| US10376504B2 (en) * | 2015-07-29 | 2019-08-13 | Merck, Sharp & Dohme Corp. | Substituted quinolinones as PDE9 inhibitors |
| WO2017019724A1 (en) * | 2015-07-29 | 2017-02-02 | Merck Sharp & Dohme Corp. | Phenyl-cyanoquinolinone pde9 inhibitors |
| EP3481399A4 (en) * | 2016-07-07 | 2020-04-01 | Cardurion Pharmaceuticals, LLC | METHOD FOR TREATING HEART INSUFFICIENCY |
| EP3296298A1 (de) * | 2016-09-14 | 2018-03-21 | Bayer Pharma Aktiengesellschaft | 7-substituierte 1-aryl-naphthyridin-3-carbonsäureamide und ihre verwendung |
| AU2018340475B2 (en) * | 2017-09-28 | 2023-01-19 | Transthera Sciences (Nanjing), Inc. | PDE9 inhibitor and use thereof |
| CN108564570A (zh) * | 2018-03-29 | 2018-09-21 | 哈尔滨工业大学（威海） | 一种智能化的病变组织定位的方法和装置 |
-
2020
- 2020-03-06 US US17/436,879 patent/US20220160696A1/en active Pending
- 2020-03-06 TW TW109107559A patent/TWI816026B/zh active
- 2020-03-06 WO PCT/CN2020/078215 patent/WO2020182076A1/zh active Application Filing
- 2020-03-06 KR KR1020217032529A patent/KR20210136104A/ko not_active Application Discontinuation
- 2020-03-06 JP JP2021553378A patent/JP7404616B2/ja active Active
- 2020-03-06 SG SG11202109781Q patent/SG11202109781QA/en unknown
- 2020-03-06 CA CA3132895A patent/CA3132895C/en active Active
- 2020-03-06 EP EP20768911.8A patent/EP3939588A4/en active Pending
- 2020-03-06 CN CN202010151837.1A patent/CN111658653B/zh active Active
- 2020-03-06 AU AU2020235187A patent/AU2020235187B8/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TW202100151A (zh) | 2021-01-01 |
| EP3939588A1 (en) | 2022-01-19 |
| WO2020182076A1 (zh) | 2020-09-17 |
| KR20210136104A (ko) | 2021-11-16 |
| JP7404616B2 (ja) | 2023-12-26 |
| US20220160696A1 (en) | 2022-05-26 |
| AU2020235187B8 (en) | 2024-02-08 |
| AU2020235187A1 (en) | 2021-10-07 |
| AU2020235187A8 (en) | 2024-02-08 |
| CA3132895A1 (en) | 2020-09-17 |
| JP2022533879A (ja) | 2022-07-27 |
| CN111658653B (zh) | 2022-09-09 |
| CA3132895C (en) | 2024-05-14 |
| EP3939588A4 (en) | 2023-01-11 |
| AU2020235187B2 (en) | 2023-09-07 |
| CN111658653A (zh) | 2020-09-15 |
| TWI816026B (zh) | 2023-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4069212A4 (en) | HIF-2 ALPHA INHIBITORS | |
| EP3600318A4 (en) | METHODS FOR USING EHMT2 INHIBITORS | |
| IL281939A (en) | VAP-1 inhibitors | |
| EP3801503A4 (en) | INHIBITORS OF SARM1 | |
| EP4034094A4 (en) | PHOSPHODIESTERASE INHIBITORS AND THEIR USE | |
| IL286218A (en) | Solid state forms of ripretinib | |
| SG11202109781QA (en) | Uses of phosphodiesterase inhibitors | |
| IL276269A (en) | Aminopyrrolotriazines as kinase inhibitors | |
| EP3638229A4 (en) | IMIDAZOLE INHIBITORS FROM ALK2-KINASE | |
| PL3700902T3 (pl) | Inhibitory trpc6 | |
| EP3906029A4 (en) | INHIBITORS OF MENIN-MLL INTERACTION | |
| SG10202006699XA (en) | Inhibition of allergic reaction using an il-33 inhibitor | |
| EP3982949A4 (en) | MRSA1 INHIBITORS | |
| EP3980011A4 (en) | MRSA1 INHIBITORS | |
| EP3801499A4 (en) | INHIBITORS OF SARM1 | |
| IL281815A (en) | VAP-1 inhibitors | |
| GB201708457D0 (en) | Inhibitors of metallo-beta-lactamases | |
| IL276312B1 (en) | Use of Alkoxypyrazoles as nitrification inhibitors | |
| IL308476A (en) | Inhibitors of the menin-mil interaction | |
| EP3801500A4 (en) | INHIBITORS OF SARM1 | |
| EP3801525A4 (en) | PROLYL-ARNT-SYNTHETASE INHIBITORS | |
| GB201708451D0 (en) | Inhibitors of metallo-beta-lactamases | |
| ZA202105399B (en) | Use of spiropidion | |
| IL277869A (en) | Substituted propanamides as nuclease inhibitors | |
| EP4055158A4 (en) | BROAD-SPECTRUM CRISPR-CAS9 INHIBITORS |